| Nicole Radabaugh, FNP | |
|
300 Minuteman Dr, Weston, WV 26452-2200 | |
| (304) 999-7870 | |
| (304) 269-0165 |
| Full Name | Nicole Radabaugh |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 300 Minuteman Dr, Weston, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003203316 | NPI | - | NPPES |
| 3810029176 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | APRN59918-NP-C (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wvu Medicine Home Health United Hospital Center | Clarksburg, WV | Home health agency |
| St Joseph's Hospital | Buckhannon, WV | Hospital |
| Stonewall Jackson Memorial Hospital | Weston, WV | Hospital |
| Entity Name | Camden On Gauley Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Public Health/welfare Agency |
| Entity Identifiers | NPI Number: 1558340414 PECOS PAC ID: 6002867850 Enrollment ID: O20050209000321 |
News Archive
After flooding in northwest Pakistan killed more than 1,500 people and displaced an estimated 300,000, leaders of the State Department and USAID are "promising an extended mission to deal with the long-term effects," Foreign Policy's "The Cable" blog reports. Secretary of State Hillary Rodham Clinton and USAID Administrator Rajiv Shah briefed reporters Wednesday about the disaster and their agencies' efforts in the region (Rogin, 8/4).
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
A European consortium of researchers studied five off-patent community and hospital antibiotics with modern methods. They integrated the results of three randomised controlled clinical trials with extensive non-clinical studies.
United Health's CEO Stephen Hemsley said he expects companies to keep offering benefits instead of pushing people to health exchanges created in 2014 by the federal government, Bloomberg Businessweek reports.
› Verified 8 days ago
| Entity Name | Camden On Gauley Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861872541 PECOS PAC ID: 6002867850 Enrollment ID: O20160125000001 |
News Archive
After flooding in northwest Pakistan killed more than 1,500 people and displaced an estimated 300,000, leaders of the State Department and USAID are "promising an extended mission to deal with the long-term effects," Foreign Policy's "The Cable" blog reports. Secretary of State Hillary Rodham Clinton and USAID Administrator Rajiv Shah briefed reporters Wednesday about the disaster and their agencies' efforts in the region (Rogin, 8/4).
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
A European consortium of researchers studied five off-patent community and hospital antibiotics with modern methods. They integrated the results of three randomised controlled clinical trials with extensive non-clinical studies.
United Health's CEO Stephen Hemsley said he expects companies to keep offering benefits instead of pushing people to health exchanges created in 2014 by the federal government, Bloomberg Businessweek reports.
› Verified 8 days ago
| Entity Name | Np 2u |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376994947 PECOS PAC ID: 3870889595 Enrollment ID: O20160907000875 |
News Archive
After flooding in northwest Pakistan killed more than 1,500 people and displaced an estimated 300,000, leaders of the State Department and USAID are "promising an extended mission to deal with the long-term effects," Foreign Policy's "The Cable" blog reports. Secretary of State Hillary Rodham Clinton and USAID Administrator Rajiv Shah briefed reporters Wednesday about the disaster and their agencies' efforts in the region (Rogin, 8/4).
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
A European consortium of researchers studied five off-patent community and hospital antibiotics with modern methods. They integrated the results of three randomised controlled clinical trials with extensive non-clinical studies.
United Health's CEO Stephen Hemsley said he expects companies to keep offering benefits instead of pushing people to health exchanges created in 2014 by the federal government, Bloomberg Businessweek reports.
› Verified 8 days ago
| Entity Name | Camden On Gauley Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427585157 PECOS PAC ID: 6002867850 Enrollment ID: O20171010003869 |
News Archive
After flooding in northwest Pakistan killed more than 1,500 people and displaced an estimated 300,000, leaders of the State Department and USAID are "promising an extended mission to deal with the long-term effects," Foreign Policy's "The Cable" blog reports. Secretary of State Hillary Rodham Clinton and USAID Administrator Rajiv Shah briefed reporters Wednesday about the disaster and their agencies' efforts in the region (Rogin, 8/4).
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
A European consortium of researchers studied five off-patent community and hospital antibiotics with modern methods. They integrated the results of three randomised controlled clinical trials with extensive non-clinical studies.
United Health's CEO Stephen Hemsley said he expects companies to keep offering benefits instead of pushing people to health exchanges created in 2014 by the federal government, Bloomberg Businessweek reports.
› Verified 8 days ago
| Entity Name | Camden On Gauley Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700312618 PECOS PAC ID: 6002867850 Enrollment ID: O20180413002227 |
News Archive
After flooding in northwest Pakistan killed more than 1,500 people and displaced an estimated 300,000, leaders of the State Department and USAID are "promising an extended mission to deal with the long-term effects," Foreign Policy's "The Cable" blog reports. Secretary of State Hillary Rodham Clinton and USAID Administrator Rajiv Shah briefed reporters Wednesday about the disaster and their agencies' efforts in the region (Rogin, 8/4).
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
A European consortium of researchers studied five off-patent community and hospital antibiotics with modern methods. They integrated the results of three randomised controlled clinical trials with extensive non-clinical studies.
United Health's CEO Stephen Hemsley said he expects companies to keep offering benefits instead of pushing people to health exchanges created in 2014 by the federal government, Bloomberg Businessweek reports.
› Verified 8 days ago
| Entity Name | Camden On Gauley Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801493499 PECOS PAC ID: 6002867850 Enrollment ID: O20230629001639 |
News Archive
After flooding in northwest Pakistan killed more than 1,500 people and displaced an estimated 300,000, leaders of the State Department and USAID are "promising an extended mission to deal with the long-term effects," Foreign Policy's "The Cable" blog reports. Secretary of State Hillary Rodham Clinton and USAID Administrator Rajiv Shah briefed reporters Wednesday about the disaster and their agencies' efforts in the region (Rogin, 8/4).
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
A European consortium of researchers studied five off-patent community and hospital antibiotics with modern methods. They integrated the results of three randomised controlled clinical trials with extensive non-clinical studies.
United Health's CEO Stephen Hemsley said he expects companies to keep offering benefits instead of pushing people to health exchanges created in 2014 by the federal government, Bloomberg Businessweek reports.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Radabaugh, FNP 10003 Webster Rd, Camden On Gauley, WV 26208-7713 Ph: (304) 226-5725 | Nicole Radabaugh, FNP 300 Minuteman Dr, Weston, WV 26452-2200 Ph: (304) 999-7870 |
News Archive
After flooding in northwest Pakistan killed more than 1,500 people and displaced an estimated 300,000, leaders of the State Department and USAID are "promising an extended mission to deal with the long-term effects," Foreign Policy's "The Cable" blog reports. Secretary of State Hillary Rodham Clinton and USAID Administrator Rajiv Shah briefed reporters Wednesday about the disaster and their agencies' efforts in the region (Rogin, 8/4).
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
A European consortium of researchers studied five off-patent community and hospital antibiotics with modern methods. They integrated the results of three randomised controlled clinical trials with extensive non-clinical studies.
United Health's CEO Stephen Hemsley said he expects companies to keep offering benefits instead of pushing people to health exchanges created in 2014 by the federal government, Bloomberg Businessweek reports.
› Verified 8 days ago
Ms. Jessica Ann Smith, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 107 Staunton Dr, Weston, WV 26452 Phone: 304-269-2022 Fax: 304-269-2037 | |
Sheree Tiffany Gruber, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 936 Sharpe Hospital Rd, Weston, WV 26452 Phone: 304-269-1210 | |
Mrs. Brittany Lynn Gregory, RN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 230 Hospital Plz, Weston, WV 26452 Phone: 304-269-8000 | |
Leigh Anne Jackson, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 230 Hospital Plz, Weston, WV 26452 Phone: 304-269-0030 | |
Stephanie Dawn Barker, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 230 Hospital Plz, Weston, WV 26452 Phone: 304-269-8000 | |
Jennifer Kathleen Frazier, PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 936 Sharpe Hospital Rd, Weston, WV 26452 Phone: 304-269-1210 Fax: 304-269-6235 |